THBD
Thrombomodulin
Also known as: BDCA-3, CD141, THRM, TRBM_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P07204
- Gene
- THBD
- Ensembl
- ENSG00000178726
- Chromosome
- 20
- Canonical length
- 575 aa
- Protein class
- Candidate cardiovascular disease genes, CD markers, Disease related genes, Human disease related genes, Predicted membrane proteins
- Subcellular location
- Nucleoplasm,Cytosol
OverviewNCBI Gene
The protein encoded by this intronless gene is an endothelial-specific type I membrane receptor that binds thrombin. This binding results in the activation of protein C, which degrades clotting factors Va and VIIIa and reduces the amount of thrombin generated. Mutations in this gene are a cause of thromboembolic disease, also known as inherited thrombophilia. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
575 residues, UniProt reviewed canonical sequence.
>P07204|THBD
1 MLGVLVLGAL ALAGLGFPAP AEPQPGGSQC VEHDCFALYP GPATFLNASQ ICDGLRGHLM
61 TVRSSVAADV ISLLLNGDGG VGRRRLWIGL QLPPGCGDPK RLGPLRGFQW VTGDNNTSYS
121 RWARLDLNGA PLCGPLCVAV SAAEATVPSE PIWEEQQCEV KADGFLCEFH FPATCRPLAV
181 EPGAAAAAVS ITYGTPFAAR GADFQALPVG SSAAVAPLGL QLMCTAPPGA VQGHWAREAP
241 GAWDCSVENG GCEHACNAIP GAPRCQCPAG AALQADGRSC TASATQSCND LCEHFCVPNP
301 DQPGSYSCMC ETGYRLAADQ HRCEDVDDCI LEPSPCPQRC VNTQGGFECH CYPNYDLVDG
361 ECVEPVDPCF RANCEYQCQP LNQTSYLCVC AEGFAPIPHE PHRCQMFCNQ TACPADCDPN
421 TQASCECPEG YILDDGFICT DIDECENGGF CSGVCHNLPG TFECICGPDS ALARHIGTDC
481 DSGKVDGGDS GSGEPPPSPT PGSTLTPPAV GLVHSGLLIG ISIASLCLVV ALLALLCHLR
541 KKQGAARAKM EYKCAAPSKE VVLQHVRTER TPQRLLocalizationUniProt · AlphaFold · HPA
Whether an antibody against THBD can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.41
- Highest tissue expression
- 69 nTPM
Expression across tissuesHPA
Tissue
- skin: 69 nTPM
- blood vessel: 66 nTPM
- adipose tissue: 65 nTPM
- lung: 54 nTPM
- spleen: 41 nTPM
- skeletal muscle: 40 nTPM
Single-cell type
- monocytes: 278 nCPM
- peritubular myoid cells: 269 nCPM
- vascular endothelial cells: 246 nCPM
- lymphatic endothelial cells: 246 nCPM
- leydig cells: 129 nCPM
- macrophages: 104 nCPM
Immune cell
- neutrophil: 25 nTPM
- plasmacytoid DC: 11 nTPM
- myeloid DC: 10 nTPM
- intermediate monocyte: 9 nTPM
- non-classical monocyte: 8.8 nTPM
- classical monocyte: 4.1 nTPM
Brain region
- thalamus: 17 nTPM
- medulla oblongata: 7.7 nTPM
- cerebral cortex: 7.1 nTPM
- choroid plexus: 6.4 nTPM
- hypothalamus: 5.3 nTPM
- spinal cord: 5.2 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about THBD.
Disease | AllUniProt
Conditions THBD is implicated in, by any mechanism.
- Thrombophilia due to thrombomodulin defect (THPH12) MIM:614486
- Hemolytic uremic syndrome, atypical, 6 (AHUS6) MIM:612926
Disease | GeneticClinVar
8 pathogenic / likely-pathogenic of 702 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Thrombomodulin-related bleeding disorder
- Abnormal bleeding
- Atypical hemolytic-uremic syndrome with thrombomodulin anomaly
- Thrombocytopenia
- See cases
Disease | AutoantibodyPubMed
Conditions in which antibodies against THBD are reported. Each links to that disease's full target list.
ReferencesPubMed · IEDB
Publications for THBD from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
6 publications
- Autoantibodies directed against the epidermal growth factor-like domains of thrombomodulin inhibit protein C activation in vitro.
1993 · Br J Haematol · RCR 1.5 · 43 citations - Autoantibodies to thrombomodulin: development of an enzyme immunoassay and a survey of their frequency in patients with the lupus anticoagulant.
1992 · Thromb Haemost · RCR 1.2 · 29 citations - Antibodies to thrombomodulin are found in patients with lupus anticoagulant and unexplained thrombosis.
2000 · J Rheumatol · RCR 0.6 · 20 citations - Synergistic thrombotic risk of antibodies against phosphatidylserine and prothrombin and β-2-glycoprotein I.
2014 · Clin Appl Thromb Hemost · RCR 0.3 · 6 citations - Anti-thrombomodulin antibodies and venous thrombosis.
2004 · Blood Coagul Fibrinolysis · RCR 0.3 · 11 citations
Show 1 more
- A search for autoantibodies to thrombomodulin in patients with documented thrombosis.
1992 · Thromb Haemost · RCR 0 · 1 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.79
- gnomAD pLI
- 0.05
- gnomAD missense Z
- 0.6
- DepMap mean gene effect
- -0.03
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- blood coagulation
- blood coagulation, common pathway
- female pregnancy
- negative regulation of blood coagulation
- negative regulation of fibrinolysis
- negative regulation of platelet activation
- proteolysis
- response to cAMP
- response to lipopolysaccharide
- response to X-ray
- zymogen activation
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- EGF-type aspartate/asparagine hydroxylation site
- EGF-like domain
- C-type lectin-like
- EGF-like calcium-binding domain
- Growth factor receptor cysteine-rich domain superfamily
- C-type lectin-like/link domain superfamily
- C-type lectin fold
- EGF-like calcium-binding, conserved site
- Complement Clr-like EGF domain
- NOTCH1, EGF-like calcium-binding domain
- Thrombomodulin-like domain
- Lectin C-type domain
- Calcium-binding EGF domain
- Complement Clr-like EGF-like
- Coagulation Factor Xa inhibitory site
- Thrombomodulin-like domain
- Thrombomodulin-like, EGF-like
- Spindle_Organization_and_Thrombomodulin
- Thrombomodulin like fifth domain, EGF-like
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of THBD in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads THBD as an antibody target. Whether an autoantibody or antibody against THBD could matter depends on whether native THBD is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
THBD is annotated at the cell surface, where native THBD is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label THBD as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...